Innovating Works

HS-SEQ

Financiado
HEPARIN AND HEPARAN SULPHATE FROM SEQUENCE DETERMINATION TO THERAPEUTIC STRATEG...
HEPARIN AND HEPARAN SULPHATE FROM SEQUENCE DETERMINATION TO THERAPEUTIC STRATEGIES FOR PARKINSON S DISEASE Heparin and heparan sulphate (HS) are highly sulfated polysaccharides that reside on the cell surface and extracellular matrix of all mammalian cell types. Understanding their functions has tremendous potential to unlock the next... Heparin and heparan sulphate (HS) are highly sulfated polysaccharides that reside on the cell surface and extracellular matrix of all mammalian cell types. Understanding their functions has tremendous potential to unlock the next generation of heparin-based diagnostics and therapeutics for multiple diseases including inflammatory and neurological diseases, cancer, and wound healing. Despite this promise, it is very difficult to harness this biomedical potential due to a fundamental technology bottleneck - lack of methods for the sequencing of HS structures to define the natural HS codes that underpin many biological functions. HS-SEQ will address this hurdle and will place Europe in the leading position in the emerging field of glycomics of heparin and HS. It is our vision that robust sequencing methods for heparin and HS will only be possible when new instrumentation will be developed that can simultaneously record multiple molecular properties such as molecular weight by mass spectrometry (MS), collisional cross sections (CCS) by ion mobility spectroscopy (IMS) and vibrational properties by gas-phase infra-red (IR) ion spectroscopy. To implement such a platform, large collections of well-defined HS saccharide standards are needed to generate reference databases that can match molecular properties to structural features. To obtain the required collection of HS saccharides, HS-SEQ will develop and implement an automated platform for chemoenzymatic synthesis of such compounds. The synthetic HS saccharides will also provide unique opportunities to develop an antibody toolkit to identify epitopes expressed by cells/tissues. Specific transformational applications of the new technology will be pursued: (i) identify HS codes that promote the generation of dopaminergic neurons from human pluripotent stem cells (hPSCs) for cell replacement therapy in Parkinson’s disease; and (ii) achieve unprecedented in-depth analysis of pharmaceutical and next-generation heparins. ver más
30/09/2024
UU
4M€
Duración del proyecto: 52 meses Fecha Inicio: 2020-05-28
Fecha Fin: 2024-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
FETOPEN-01-2018-2019-2020: FET-Open Challenging Current Thinking
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
UNIVERSITEIT UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5